Evidence map›Paper›PMID 37504313›Full record

ArticleCurrent oncology (Toronto, Ont.)2023

Plasma Thermogram Parameters Differentiate Status and Overall Survival of Melanoma Patients.

Taylor Q Nguyen, Gabriela Schneider, Alagammai Kaliappan, Robert Buscaglia, Guy N Brock, Melissa Barousse Hall, Donald M Miller, Jason A Chesney, Nichola C Garbett

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Taylor Q NguyenUofL Health-Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
Gabriela SchneiderUofL Health-Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
Alagammai KaliappanUofL Health-Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
Robert BuscagliaDepartment of Mathematics and Statistics, Northern Arizona University, Flagstaff, AZ 86011, USA.ORCID 0000-0001-9325-1148
Guy N BrockDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0001-5317-079X
Melissa Barousse HallUofL Health-Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.ORCID 0000-0001-8283-9210
Donald M MillerUofL Health-Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
Jason A ChesneyUofL Health-Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
Nichola C GarbettUofL Health-Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.ORCID 0000-0002-8097-554X

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve HealthUL1TR002733 · NCATS · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2018 to 2022
$28.9M
Enhanced diagnostic assessment in lupus using differential scanning calorimetryR01AI129959 · NIAID · UNIVERSITY OF LOUISVILLE · PI GARBETT, NICHOLA C. · 2017 to 2021
$1.8M
Plasma DSC for early detection of disease and therapeutic efficacy in melanomaR21CA187345 · NCI · UNIVERSITY OF LOUISVILLE · PI GARBETT, NICHOLA C. · 2014 to 2015
$359k
NCATS NIH HHS UL1 TR002733NCI NIH HHS P30 CA016058NCI NIH HHS R21 CA187345NIAID NIH HHS R01 AI129959
6 · The paper itself

Abstract

Melanoma is the fifth most common cancer in the United States and the deadliest of all skin cancers. Even with recent advancements in treatment, there is still a 13% two-year recurrence rate, with approximately 30% of recurrences being distant metastases. Identifying patients at high risk for recurrence or advanced disease is critical for optimal clinical decision-making. Currently, there is substantial variability in the selection of screening tests and imaging, with most modalities characterized by relatively low accuracy. In the current study, we built upon a preliminary examination of differential scanning calorimetry (DSC) in the melanoma setting to examine its utility for diagnostic and prognostic assessment. Using regression analysis, we found that selected DSC profile (thermogram) parameters were useful for differentiation between melanoma patients and healthy controls, with more complex models distinguishing melanoma patients with no evidence of disease from patients with active disease. Thermogram features contributing to the third principal component (PC3) were useful for differentiation between controls and melanoma patients, and Cox proportional hazards regression analysis indicated that PC3 was useful for predicting the overall survival of active melanoma patients. With the further development and optimization of the classification method, DSC could complement current diagnostic strategies to improve screening, diagnosis, and prognosis of melanoma patients.

Indexed as

MelanomaSkin NeoplasmsCalorimetry, Differential ScanningHumansPrognosisUnited Statesdiagnosisdifferential scanning calorimetry (DSC)melanomano evidence of disease (NED)overall survival (OS)thermogram

Identifiers

PMID37504313
PMCPMC10378067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.